Potential Road To At-Home Psychedelics Use Permits: Low Dosing's Positive Outcomes In Phase 1 Trial
Canadian drug development company Diamond Therapeutics Inc. announced it has successfully completed its Phase 1 clinical study on low-dose psilocybin and shared the trial’s most relevant results.